SE539450C2 - Imatinib for use in the treatment of stroke - Google Patents
Imatinib for use in the treatment of stroke Download PDFInfo
- Publication number
- SE539450C2 SE539450C2 SE1650260A SE1650260A SE539450C2 SE 539450 C2 SE539450 C2 SE 539450C2 SE 1650260 A SE1650260 A SE 1650260A SE 1650260 A SE1650260 A SE 1650260A SE 539450 C2 SE539450 C2 SE 539450C2
- Authority
- SE
- Sweden
- Prior art keywords
- imatinib
- patient
- stroke
- administered
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| AU2017227515A AU2017227515B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| CN201780013732.6A CN108697711A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| LTEPPCT/SE2017/050183T LT3423060T (lt) | 2016-02-29 | 2017-02-27 | Imatinibas, skirtas naudoti insulto gydymui |
| RU2019122730A RU2739382C1 (ru) | 2016-02-29 | 2017-02-27 | Иматиниб для применения для лечения инсульта |
| SI201730931T SI3423060T1 (sl) | 2016-02-29 | 2017-02-27 | Imatinib za uporabo pri zdravljenju možganske kapi |
| PL17760399T PL3423060T3 (pl) | 2016-02-29 | 2017-02-27 | Imatynib do stosowania w leczeniu udaru mózgu |
| RS20211286A RS62465B1 (sr) | 2016-02-29 | 2017-02-27 | Imatinib za upotrebu u lečenju moždanog udara |
| CN202411509669.3A CN119523986A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| HUE17760399A HUE056798T2 (hu) | 2016-02-29 | 2017-02-27 | Imatinib stroke kezelésében való alkalmazásra |
| EP17760399.0A EP3423060B1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| DK17760399.0T DK3423060T3 (da) | 2016-02-29 | 2017-02-27 | Imatinib til anvendelse til behandling af slagtilfælde |
| US16/080,529 US10953010B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| ES17760399T ES2895432T3 (es) | 2016-02-29 | 2017-02-27 | Imatinib para uso en el tratamiento de accidente cerebrovascular |
| PT177603990T PT3423060T (pt) | 2016-02-29 | 2017-02-27 | Imatinib para utilização no tratamento de acidente vascular cerebral |
| JP2018545843A JP6914957B2 (ja) | 2016-02-29 | 2017-02-27 | 脳卒中の処置における使用のためのイマチニブ |
| HRP20211621TT HRP20211621T1 (hr) | 2016-02-29 | 2017-02-27 | Imatinib za uporabu u liječenju moždanog udara |
| US17/186,303 US20210236488A1 (en) | 2016-02-29 | 2021-02-26 | Imatinib for use in the treatment of stroke |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1650260A1 SE1650260A1 (en) | 2017-08-30 |
| SE539450C2 true SE539450C2 (en) | 2017-09-26 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (https=) |
| EP (1) | EP3423060B1 (https=) |
| JP (1) | JP6914957B2 (https=) |
| CN (2) | CN119523986A (https=) |
| AU (1) | AU2017227515B2 (https=) |
| DK (1) | DK3423060T3 (https=) |
| ES (1) | ES2895432T3 (https=) |
| HR (1) | HRP20211621T1 (https=) |
| HU (1) | HUE056798T2 (https=) |
| LT (1) | LT3423060T (https=) |
| PL (1) | PL3423060T3 (https=) |
| PT (1) | PT3423060T (https=) |
| RS (1) | RS62465B1 (https=) |
| RU (1) | RU2739382C1 (https=) |
| SE (1) | SE539450C2 (https=) |
| SI (1) | SI3423060T1 (https=) |
| WO (1) | WO2017151043A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| CA3238590A1 (en) * | 2021-11-09 | 2023-05-19 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| US8147828B2 (en) * | 2006-04-17 | 2012-04-03 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| EP1966186A1 (en) * | 2006-10-26 | 2008-09-10 | Sicor Inc. | Process for the preparation of imatinib |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| JP2012521984A (ja) * | 2009-03-27 | 2012-09-20 | モリーク ピーティーイー リミテッド | 細胞成長を促進するための治療 |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/en not_active IP Right Cessation
-
2017
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN108697711A (zh) | 2018-10-23 |
| DK3423060T3 (da) | 2021-10-25 |
| AU2017227515B2 (en) | 2022-03-24 |
| PL3423060T3 (pl) | 2022-01-10 |
| US20210236488A1 (en) | 2021-08-05 |
| SE1650260A1 (en) | 2017-08-30 |
| WO2017151043A1 (en) | 2017-09-08 |
| ES2895432T3 (es) | 2022-02-21 |
| RS62465B1 (sr) | 2021-11-30 |
| EP3423060B1 (en) | 2021-07-21 |
| JP2019507165A (ja) | 2019-03-14 |
| LT3423060T (lt) | 2021-11-10 |
| SI3423060T1 (sl) | 2021-11-30 |
| US10953010B2 (en) | 2021-03-23 |
| JP6914957B2 (ja) | 2021-08-04 |
| EP3423060A4 (en) | 2020-01-01 |
| PT3423060T (pt) | 2021-10-20 |
| RU2739382C1 (ru) | 2020-12-23 |
| EP3423060A1 (en) | 2019-01-09 |
| US20190030030A1 (en) | 2019-01-31 |
| AU2017227515A1 (en) | 2018-08-30 |
| HRP20211621T1 (hr) | 2022-02-04 |
| HUE056798T2 (hu) | 2022-03-28 |
| CN119523986A (zh) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210236488A1 (en) | Imatinib for use in the treatment of stroke | |
| Diringer et al. | Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit | |
| JP7810762B2 (ja) | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 | |
| JP7082115B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| Saito et al. | Continuous oral administration of atorvastatin ameliorates brain damage after transient focal ischemia in rats | |
| AU2007218709A1 (en) | Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke | |
| Awad et al. | Dabigatran, intracranial hemorrhage, and the neurosurgeon | |
| Wang et al. | Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial | |
| Takeuchi et al. | Decompressive craniectomy for arteriovenous malformation-related intracerebral hemorrhage | |
| RU2542455C2 (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| RU2821032C1 (ru) | Способы лечения заболеваний, связанных с рецептором s1p1 | |
| RU2845317C1 (ru) | Способ лечения постковидного синдрома | |
| AL SHAMSI et al. | WCN23-0109 MANAGEMENT OF ASYMPTOMATIC ANGIOMYOLIPOMA IN PREGNANCY | |
| Naeem et al. | Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism | |
| CN115475165B (zh) | 马来酸茚达特罗在出血性脑损伤相关疾病中的应用 | |
| ALLAM | WCN23-0127 KIDNEY OUT COMES IN SUDANSES CHILDREN WITH LUPUS NEPHRITIES | |
| Alkanat et al. | Dermatologic Reactions Following COVID-19 Vaccination: A Case Series | |
| IVH | Special Disease Management | |
| KR20250114057A (ko) | 맥관 기형용 의약 조성물 및 맥관 기형의 치료 방법 | |
| Storment et al. | Tranexamic Acid (TA) | |
| Katayoun Vahedi | Surgery for acute ischemic stroke | |
| Rahman et al. | Effect of Tamsulosin on Treatment of Lower Ureteric Calculi | |
| CN121221781A (zh) | 一种用于预防胆囊结石的药物组合物 | |
| Sung et al. | Rhabdomyolysis after cerebral perfusion pressure-guided management in severe head injury | |
| Dadlani et al. | Introductory Chapter: An Introduction to Hypertension-Related Intracerebral Hematomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |